H.C. Wainwright analyst Arthur He downgraded BioAtla (BCAB) to Neutral from Buy without a price target The firm is awaiting clarity on the company’s pipeline development path. The firm says that with pipeline decisions pending, it is unable to project the cadence of BioAtla’s revenue at this time.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB: